News

  • 21 May 2019

    Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, will announce the results of the first-in-human single dose DSR (Direct Sodium Removal) proof-of-concept study for volume overload in heart failure following the late-breaking presentation at the Heart Failure 2019 congress on 27 May 2019.

    (....)

  • 21 May 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced the publication of preclinical efficacy data with GKT831 for cholestatic fibrosis. The article “Activated Hepatic Stellate Cells and Portal Fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice” was published in the Journal of Hepatology1 . 

  • 15 May 2019

    Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces that the alfapump has been included in the DGVS (“German Society of Gastroenterology Digestive and Metabolic Diseases”) guidelines for complications of liver cirrhosis. These guidelines provide evidence-based key recommendations for diagnosis and therapy of complications of liver cirrhosis and upgrade the 2011 version. An interdisciplinary team of medical experts and patient support groups developed the guidelines following the recommendations by the Association of Scientific Medical Societies for evidence-based consensus guidelines.

  • 15 May 2019

    X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and The Leukemia & Lymphoma Society (LLS) today announced a collaboration to accelerate the development of X4’s lead product candidate, mavorixafor (X4P-001) for the treatment of Waldenström’s macroglobulinemia (WM), a rare form of non-Hodgkin lymphoma.

  • 14 May 2019

    Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced biopsy data from its recent Phase 2b clinical trial with SNA-120 (pegcantratinib), the Company’s Phase 3 topical, non-steroidal Tropomyosin receptor kinase A (TrkA) inhibitor under investigation for the treatment of psoriasis. Biopsy analyses were conducted at The Rockefeller University on 22 subjects, and included Immunohistochemistry (IHC), MicroArray and quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR).